Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Eagle Pharmaceuticals (EGRX) PT Lowered to $64 at RBC Capital
November 2, 2018 7:01 AM EDTRBC Capital analyst Randall Stanicky lowered the price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $64.00 (from $84.00) while maintaining an Outperform rating.
Stanicky said results place a spotlight on recent pipeline setbacks and outlook.
... MoreEagle Pharmaceuticals (EGRX) Misses Q3 EPS by 7c, Revenues Miss
November 1, 2018 6:51 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.91, $0.07 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.23 million.
While we were disappointed in the outcome of the fulvestrant trial, we believe in the strength of the remaining products in our pipeline and... More
